Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5961938 | PMC |
| http://dx.doi.org/10.1016/j.jaad.2017.07.053 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diuresis During F-Flotufolastat (rhPSMA-7.3) PET/CT Improves Recurrence Detection After Prostatectomy: A Prospective Phase II Trial.
J Nucl Med
January 2025
Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.
Radiopharmaceuticals targeting prostate-specific membrane antigen (PSMA) have emerged as a sensitive tool for PET imaging of prostate cancer (PCa) recurrence. Yet urinary bladder activity may obscure the visualization of prostate bed recurrence. Among the Food and Drug Administration-approved PSMA radiopharmaceuticals, F-flotufolastat (rhPSMA-7.
View Article and Find Full Text PDFExploring low-dose glucagon for exercise-induced hypoglycaemia in type 1 diabetes: A randomised controlled trial.
Diabet Med
January 2025
Steno Diabetes Center Copenhagen, Clinical Translational Research, Diabetes Technology Research, Herlev, Denmark.
Aims: This study was designed to compare the effectiveness of a single subcutaneous (s.c.) glucagon dose versus the same total dose split into a dose before and after and placebo (PBO) in preventing exercise-induced hypoglycaemia in adults with type 1 diabetes (T1D).
View Article and Find Full Text PDFBayesian Sample Size Calculation in Small n, Sequential Multiple Assignment Randomized Trials (snSMART).
Pharm Stat
January 2025
Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
A recent study design for clinical trials with small sample sizes is the small n, sequential, multiple assignment, randomized trial (snSMART). An snSMART design has been previously proposed to compare the efficacy of two dose levels versus placebo. In such a trial, participants are initially randomized to receive either low dose, high dose or placebo in stage 1.
View Article and Find Full Text PDFEffect of combination therapy of methylfolate with antidepressants in patients with depressive disorder.
BMC Pharmacol Toxicol
January 2025
Department of Community Medicine, Islamic International Medical College (IIMC), Riphah International University, Rawalpindi, Pakistan.
Objective: To determine the relative effectiveness of combination therapy of antidepressants with low-dose methylfolate versus antidepressant monotherapy in patients with depressive disorder.
Methods: In an open-label clinical trial, forty-four patients with depressive disorder (6A70, 6A71, and 6A72 according to ICD-11) received an evidence-based antidepressant therapy (either escitalopram 10-20 mg, sertraline 50-100 mg, fluoxetine 20-40 mg, duloxetine 30-60 mg, mirtazapine 15-30 mg, venlafaxine 75-150 mg, trazodone 50-100 mg, amitriptyline 25-75 mg, or clomipramine 25-75 mg orally daily for 4 weeks). The experimental group, Group B was additionally given a dose of methylfolate 800 µg daily for four weeks.
Clinical Outcomes with High- versus Low-Dose Tranexamic Acid Infusion in Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-Analysis.
Thorac Cardiovasc Surg
January 2025
Department of Medicine, MedStar Health, Baltimore, Maryland, United States.
Objectives: Antifibrinolytics, such as tranexamic acid (TXA), are widely used in cardiac surgery to reduce bleeding risks; however, the optimal dosage for TXA infusion remains a subject of debate. Hence, this study aims to evaluate the safety and efficacy of high-dose compared with low-dose TXA infusion in cardiac surgery patients.
Methods: PubMed, SCOPUS, and Cochrane Central Register of Controlled Trials (CENTRAL) were searched until June 10, 2023, for studies assessing efficacy outcomes (e.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!